Hainan Huluwa Pharmaceutical Group Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.060x

Hainan Huluwa Pharmaceutical Group Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥44.34 Million ≈ $6.49 Million USD) by net assets (CN¥735.65 Million ≈ $107.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

Cash flow conversion efficiency of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 605199 stock price for real-time trading data and today's change.

Hainan Huluwa Pharmaceutical Group Co Ltd Cash Flow Conversion Ratio Explained

Hainan Huluwa Pharmaceutical Group Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency. Also see Hainan Huluwa Pharmaceutical Group Co Lt market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
All For One Steeb AG F:A1OS	0.059x
Shenke Slide Bearing Corp SHE:002633	0.031x
Guangdong Dcenti Auto-Parts Stock Ltd Co SHG:603335	0.088x
Metropolitan Land Tbk JK:MTLA	0.010x
Gospell Digital Technology Co Ltd SHE:002848	-0.099x
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	-0.048x
Jerusalem TA:JBNK	0.033x
K&F Growth Acquisition Corp. II Class A Ordinary shares NASDAQ:KFII	0.000x

Annual Cash Flow Conversion Efficiency for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. Review 605199 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥458.02 Million ≈ $67.02 Million	CN¥136.85 Million ≈ $20.03 Million	0.299x	+248.94%
2024-12-31	CN¥743.28 Million ≈ $108.77 Million	CN¥-149.12 Million ≈ $-21.82 Million	-0.201x	-923.26%
2023-12-31	CN¥1.16 Billion ≈ $169.65 Million	CN¥28.25 Million ≈ $4.13 Million	0.024x	-89.64%
2022-12-31	CN¥1.02 Billion ≈ $148.57 Million	CN¥238.71 Million ≈ $34.93 Million	0.235x	+113.48%
2021-12-31	CN¥930.52 Million ≈ $136.16 Million	CN¥102.48 Million ≈ $15.00 Million	0.110x	+2958.79%
2020-12-31	CN¥916.48 Million ≈ $134.11 Million	CN¥3.30 Million ≈ $482.88K	0.004x	-98.40%
2019-12-31	CN¥643.94 Million ≈ $94.23 Million	CN¥144.51 Million ≈ $21.15 Million	0.224x	+326.73%
2018-12-31	CN¥604.61 Million ≈ $88.47 Million	CN¥31.80 Million ≈ $4.65 Million	0.053x	-79.46%
2017-12-31	CN¥351.38 Million ≈ $51.42 Million	CN¥89.96 Million ≈ $13.16 Million	0.256x	-49.28%
2016-12-31	CN¥128.69 Million ≈ $18.83 Million	CN¥64.96 Million ≈ $9.51 Million	0.505x	--

About Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic

Market Cap

$313.82 Million

CN¥2.14 Billion CNY

Market Cap Rank

#14273 Global

#4248 in China

Share Price

CN¥5.36

Change (1 day)

+0.75%

52-Week Range

CN¥5.19 - CN¥10.04

All Time High

CN¥48.21